Thrivent Financial for Lutherans Sells 242 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Thrivent Financial for Lutherans decreased its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 1.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,815 shares of the medical instruments supplier’s stock after selling 242 shares during the period. Thrivent Financial for Lutherans owned 0.07% of LeMaitre Vascular worth $1,457,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in LMAT. New York State Teachers Retirement System lifted its position in shares of LeMaitre Vascular by 1.2% during the fourth quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier’s stock worth $755,000 after purchasing an additional 100 shares in the last quarter. Flputnam Investment Management Co. lifted its holdings in LeMaitre Vascular by 3.6% during the 4th quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier’s stock worth $269,000 after buying an additional 102 shares in the last quarter. Norden Group LLC boosted its position in LeMaitre Vascular by 4.5% in the 4th quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier’s stock valued at $218,000 after buying an additional 103 shares during the last quarter. Blue Barn Wealth LLC increased its stake in shares of LeMaitre Vascular by 4.4% in the 4th quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier’s stock valued at $229,000 after buying an additional 104 shares during the period. Finally, Shaker Investments LLC OH increased its stake in shares of LeMaitre Vascular by 0.8% in the 4th quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier’s stock valued at $1,285,000 after buying an additional 112 shares during the period. Institutional investors own 84.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on LMAT shares. Lake Street Capital raised their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a report on Friday, February 28th. Oppenheimer lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price objective on the stock. Finally, Barrington Research cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Five analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, LeMaitre Vascular has a consensus rating of “Moderate Buy” and an average target price of $95.25.

LeMaitre Vascular Stock Performance

Shares of NASDAQ LMAT opened at $83.05 on Monday. LeMaitre Vascular, Inc. has a 52-week low of $62.39 and a 52-week high of $109.58. The stock has a market cap of $1.87 billion, a P/E ratio of 45.38, a P/E/G ratio of 2.22 and a beta of 0.89. The firm has a 50 day moving average price of $93.07 and a 200 day moving average price of $94.42.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.49. The company had revenue of $55.81 million during the quarter, compared to analyst estimates of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. Analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were given a dividend of $0.20 per share. The ex-dividend date was Thursday, March 13th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.96%. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 41.24%.

Insider Activity

In other news, insider Trent G. Kamke sold 2,009 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares of the company’s stock, valued at $456,915.68. This represents a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.79% of the stock is currently owned by company insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.